Bioxytran Q1 2026 Earnings Report

Bioxytran EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bioxytran Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bioxytran Announcement Details

• Quarter: Q1 2026
• Date: 5/15/2026
• Time: During Market Hours
• Conference Call Date: Friday, May 15, 2026
• Conference Call Time: 7:00AM ET

Bioxytran (OTCMKTS:BIXT) is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release. These formulations are engineered to minimize oxidative stress and inflammation while enhancing tissue recovery. The company maintains a patent portfolio covering key geographies, including North America, Europe, and Asia, and is actively exploring collaborative partnerships to support development and potential global commercialization.

Originating from foundational work in synthetic oxygen therapeutics, Bioxytran has transitioned from early-stage research into a specialized biopharmaceutical developer. The management team brings together expertise in biotechnology R&D, regulatory strategy, and manufacturing scale-up. Bioxytran continues to pursue strategic alliances and funding initiatives to advance its mission of delivering innovative oxygen-based therapies that improve patient outcomes in critical therapeutic areas.